Zager Jonathan S, Orloff Marlana, Ferrucci Pier Francesco, Choi Junsung, Eschelman David J, Glazer Evan S, Ejaz Aslam, Howard J Harrison, Richtig Erika, Ochsenreither Sebastian, Reddy Sunil A, Lowe Michael C, Beasley Georgia M, Gesierich Anja, Bender Armin, Gschnell Martin, Dummer Reinhard, Rivoire Michel, Arance Ana, Fenwick Stephen William, Sacco Joseph J, Haferkamp Sebastian, Weishaupt Carsten, John Johnny, Wheater Matthew, Ottensmeier Christian H
Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Department of Oncologic Sciences, University of South Florida, Morsani School of Medicine, Tampa, FL, USA.
Ann Surg Oncol. 2025 Apr 7. doi: 10.1245/s10434-025-17231-x.
Metastatic uveal melanoma (mUM) has a poor prognosis, with liver metastases typically presenting a therapeutic challenge. Melphalan/Hepatic Delivery System (Melphalan/HDS) is a drug/medical device combination used for liver-directed treatment of unresectable mUM patients. This study assessed efficacy and safety of Melphalan/HDS versus best alternative care (BAC).
Eligible patients with unresectable mUM were randomized (1:1) to receive Melphalan/HDS (3 mg/kg ideal body weight) once every 6 to 8 weeks for a maximum of 6 cycles or BAC. Due to slow enrollment and patient reluctance to receive BAC treatment, the study design was amended to a single-arm Melphalan/HDS study, and all efficacy analyses of the randomized study were treated as exploratory.
The study enrolled 85 patients. Eligible patients were randomized to receive Melphalan/HDS (n = 43) or BAC (n = 42), and 72 patients received study treatment (Melphalan/HDS [n = 40]; BAC [n = 32]). Exploratory analyses of efficacy endpoints showed numerical differences consistently favoring the Melphalan/HDS arm versus BAC (median overall survival: 18.5 vs. 14.5 months; median progression-free survival: 9.1 vs. 3.3 months; objective response rate: 27.5% vs. 9.4%; and disease control rate: 80.0% vs. 46.9%). Serious adverse events (SAEs) occurred in 51.2% of Melphalan/HDS and in 21.9% of BAC patients. The most common (>5%) SAEs included thrombocytopenia (19.5%), neutropenia (9.8%), leukopenia (9.8%) and febrile neutropenia (7.3%) in Melphalan/HDS patients and cholecystitis, nausea and vomiting (6.3% each) in BAC patients. No treatment-related deaths were observed.
Treatment with Melphalan/HDS shows clinically meaningful efficacy and demonstrates a favorable benefit-risk profile in patients with unresectable mUM as compared to BAC.
转移性葡萄膜黑色素瘤(mUM)预后较差,肝转移通常带来治疗挑战。美法仑/肝递送系统(Melphalan/HDS)是一种用于不可切除mUM患者肝靶向治疗的药物/医疗器械组合。本研究评估了Melphalan/HDS与最佳替代治疗(BAC)的疗效和安全性。
符合条件的不可切除mUM患者按1:1随机分组,每6至8周接受一次Melphalan/HDS(3mg/kg理想体重),最多6个周期,或接受BAC治疗。由于入组缓慢且患者不愿接受BAC治疗,研究设计修改为单臂Melphalan/HDS研究,随机研究的所有疗效分析均作为探索性分析。
该研究共纳入85例患者。符合条件的患者被随机分配接受Melphalan/HDS(n = 43)或BAC(n = 42),72例患者接受了研究治疗(Melphalan/HDS [n = 40];BAC [n = 32])。疗效终点的探索性分析显示,数值差异始终有利于Melphalan/HDS组而非BAC组(中位总生存期:18.5个月对14.5个月;中位无进展生存期:9.1个月对3.3个月;客观缓解率:27.5%对9.4%;疾病控制率:80.0%对46.9%)。Melphalan/HDS组51.2%的患者和BAC组21.9%的患者发生了严重不良事件(SAEs)。Melphalan/HDS组最常见(>5%)的SAEs包括血小板减少症(19.5%)、中性粒细胞减少症(9.8%)、白细胞减少症(9.8%)和发热性中性粒细胞减少症(7.3%),BAC组为胆囊炎、恶心和呕吐(各6.3%)。未观察到与治疗相关的死亡。
与BAC相比,Melphalan/HDS治疗在不可切除mUM患者中显示出具有临床意义的疗效,并表现出良好的获益-风险特征。